Clinical trial registry
ClinicalTrials.gov
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma (BATTMAN)
What is it about?
The BATTMAN trial is a Phase 3 clinical trial testing a new cancer treatment idea using a combination of two immunotherapy drugs, botensilimab and balstilimab, for people with a very hard-to-treat type of cancer called chemo-refractory, unresectable microsatellite stable (MSS) metastatic colorectal cancer (a kind of bowel cancer that has spread and no longer responds to standard chemotherapy).
In the trial, people will be randomly put into one of two groups:
• One group gets the new BOT + BAL treatment along with the usual supportive care to help with symptoms.
• The other group gets best supportive care alone, which focuses on comfort and quality of life rather than trying a new cancer-fighting medicine.
Doctors will then compare how long patients live (called overall survival) and other outcomes like how well tumors respond to treatment, how long people go without the cancer growing, quality of life, and side effects.
Why is it important?
This trial is important because current options for people with this type of advanced colorectal cancer are very limited and often don’t help much. Earlier studies of BOT + BAL have shown encouraging signs that the combination might help the immune system fight tumors that haven’t responded to other immunotherapies, with some patients living significantly longer than expected.
If this trial shows that BOT + BAL helps patients live longer or feel better than best supportive care alone, it could lead to a new treatment option for people who today have very few. This trial is registered on the US government clinical trial website ClinicalTrials.gov with the ID: NCT07152821. IT has not yet started recruiting patients. If you want to know more about the trial you can contact the company responsible for the trial, Agenus, here: https://www.agenusbio.com/contact-medical-affairs.
This is a demo page.
